View Filing Data

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2017	Jul. 31, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Xenon Pharmaceuticals Inc.
Document Type	10-Q
Trading Symbol	XENE
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001582313
Entity Filer Category	Accelerated Filer
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Entity Common Stock, Shares Outstanding		17,998,420

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 23,090	$ 17,095
Marketable securities	28,606	47,051
Accounts receivable	198	200
Prepaid expenses and other current assets	739	1,329
Total current assets	52,633	65,675
Prepaid expenses, long term	285	408
Property, plant and equipment, net	1,308	1,404
Total assets	54,226	67,487
Current liabilities:
Accounts payable and accrued expenses (note 6)	3,774	3,586
Total liabilities	3,774	3,586
Shareholders’ equity:
Common shares, without par value; unlimited shares authorized; issued and outstanding: 17,998,420 (December 31, 2016 - 17,930,590) (note 7a)	173,841	173,246
Additional paid-in capital	35,182	34,326
Accumulated deficit	(157,581)	(142,681)
Accumulated other comprehensive loss	(990)	(990)
Shareholders' equity	50,452	63,901
Total liabilities and shareholders’ equity	54,226	67,487
Commitments and contingencies (note 9)

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Common shares, without par value
Common shares, shares authorized	Unlimited	Unlimited
Common shares, Issued	17,998,420	17,930,590
Common shares, Outstanding	17,998,420	17,930,590

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue:
Collaboration revenue (note 8)	$ 15	$ 412	$ 30	$ 981
Royalties		1	1	33
Revenues	15	413	31	1,014
Operating expenses:
Research and development	6,109	5,103	12,012	9,467
General and administrative	1,799	1,676	3,899	3,571
Total operating expenses	7,908	6,779	15,911	13,038
Loss from operations	(7,893)	(6,366)	(15,880)	(12,024)
Other income:
Interest income	109	123	258	222
Foreign exchange gain	404	227	725	2,523
Net loss and comprehensive loss	$ (7,380)	$ (6,016)	$ (14,897)	$ (9,279)
Net loss per common share (note 4):
Basic	$ (0.41)	$ (0.42)	$ (0.83)	$ (0.64)
Diluted	$ (0.41)	$ (0.42)	$ (0.84)	$ (0.65)
Weighted-average common shares outstanding (note 4):
Basic	17,997,194	14,408,108	17,971,702	14,401,054
Diluted	18,015,748	14,434,602	17,995,109	14,428,160

Consolidated Statement of Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands

Total

Common Shares [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit [Member]

Accumulated Other Comprehensive Loss [Member]

^[1]

Balance at Dec. 31, 2015

$ 61,034

$ 148,634

$ 33,083

$ (119,693)

$ (990)

Balance (in Shares) at Dec. 31, 2015

14,385,336

Net loss

(22,997)

Issuance of common shares, net of issuance costs

23,832

$ 23,832

Issuance of common shares, net of issuance costs (in Shares)

3,450,000

Stock-based compensation expense

2,186

Issued pursuant to exercise of stock options

132

$ 780

(657)

Issued pursuant to exercise of stock options (in Shares)

95,254

Fair value adjustment upon reclassification of stock options

(286)

Balance at Dec. 31, 2016

63,901

$ 173,246

34,326

(142,681)

(990)

Balance (in Shares) at Dec. 31, 2016

17,930,590

Net loss

(14,897)

Stock-based compensation expense

1,271

Issued pursuant to exercise of stock options

$ 177

$ 595

(415)

(3)

Issued pursuant to exercise of stock options (in Shares)

71,006

^[2]

67,830

Balance at Jun. 30, 2017

$ 50,452

$ 173,841

$ 35,182

$ (157,581)

$ (990)

Balance (in Shares) at Jun. 30, 2017

17,998,420

[1]	Our accumulated other comprehensive loss is entirely related to historical cumulative translation adjustments from the application of U.S. dollar reporting when the functional currency of the Company was the Canadian dollar.
[2]	During the six months ended June 30, 2017, 63,425 stock options were exercised for the same number of common shares for cash (six months ended June 30, 2016 – 29,270). In the same period, the Company issued 4,405 common shares (six months ended June 30, 2016 – 741) for the cashless exercise of 7,581 stock options (six months ended June 30, 2016 – 1,259).

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating activities:
Net loss	$ (14,897)	$ (9,279)
Items not involving cash:
Depreciation and amortization	334	531
Stock-based compensation	1,076	1,006
Unrealized foreign exchange gain	(819)	(2,508)
Changes in operating assets and liabilities:
Accounts receivable	5	(333)
Prepaid expenses, and other current assets	590	(96)
Prepaid expenses, long term	123	462
Accounts payable and accrued expenses	326	1
Deferred revenue		(157)
Net cash used in operating activities	(13,262)	(10,373)
Investing activities:
Purchases of property, plant and equipment	(238)	(205)
Purchase of marketable securities	(22,281)	(15,300)
Proceeds from marketable securities	41,099
Net cash provided by (used in) investing activities	18,580	(15,505)
Financing activities:
Issuance of common shares pursuant to exercise of stock options	177	82
Net cash provided by financing activities	177	82
Effect of exchange rate changes on cash and cash equivalents	500	2,355
Increase (decrease) in cash and cash equivalents	5,995	(23,441)
Cash and cash equivalents, beginning of period	17,095	58,651
Cash and cash equivalents, end of period	23,090	35,210
Supplemental disclosures:
Interest received	457	204
Supplemental disclosures of non-cash transactions:
Fair value of options exercised on a cashless basis	$ 25	$ 4

Nature of the Business

6 Months Ended

Jun. 30, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Nature of the business

1.	Nature of the business:

Xenon Pharmaceuticals Inc. (the “Company”), incorporated in 1996 under the British Columbia Business Corporations Act and continued federally in 2000 under the Canada Business Corporation Act, is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that it intends to commercialize on its own, and for larger market indications that it intends to partner with global pharmaceutical companies.

Basis of Presentation

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Basis of presentation

2.	Basis of presentation:

These consolidated financial statements are presented in U.S. dollars.

The Company has one wholly-owned subsidiary as at June 30, 2017, Xenon Pharmaceuticals USA Inc., which was incorporated in Delaware on December 2, 2016.

These unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions and balances have been eliminated on consolidation.

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, these consolidated financial statements do not include all of the information and footnotes required for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and notes for the year ended December 31, 2016 and included in the Company’s 2016 Annual Report on Form 10-K filed with the SEC and with the securities commissions in British Columbia, Alberta and Ontario on March 8, 2017.

These unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and six month periods ended June 30, 2017 and 2016 are not necessarily indicative of results that can be expected for a full year. These unaudited interim consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company included in the Company’s 2016 Annual Report on Form 10-K for the year ended December 31, 2016. Certain comparative figures have been reclassified to conform to the consolidated financial statement presentation adopted for the current period.

Future Changes in Accounting Policies

6 Months Ended

Jun. 30, 2017

Accounting Changes And Error Corrections [Abstract]

Future changes in accounting policies

3.	Future changes in accounting policies:

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC 606) to clarify the principles of recognizing revenue and to develop a common revenue standard that would remove inconsistencies in revenue requirements, leading to improved comparability of revenue recognition practices across entities and industries. The standard, as subsequently amended, stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new guidance will be effective for public entities for fiscal years and interim periods within those years, beginning after December 15, 2017. The Company has begun its evaluation and identified two significant collaboration agreements with respect to revenue, the collaborative development and license agreements with Teva Pharmaceutical Industries, Ltd. and Genentech, a member of the Roche Group, described in notes 9(a) and (b), respectively, to the audited consolidated financial statements of the Company included in the Company’s 2016 Annual Report on Form 10-K for the year ended December 31, 2016. The Company is evaluating the new guidance as it applies to revenue previously recognized as well as milestone payments the Company is eligible to receive in future periods under these agreements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842): Recognition and Measurement of Financial Assets and Financial Liabilities. The update requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous U.S. GAAP. The new guidance retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. These amendments will be effective for public entities for fiscal years and interim periods within those years, beginning after December 15, 2018. The Company is currently evaluating the new guidance to determine the impact it will have on the Company’s consolidated financial statements.

Net Income (Loss) Per Common Share

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Net income (loss) per common share

4.	Net income (loss) per common share:

Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per common share is computed by adjusting the numerator and denominator of the basic net income (loss) per share calculation for the potential impact of dilutive securities.

For the three and six month periods ended June 30, 2017, 2,228,637 and 2,086,072 stock options, respectively, were excluded from the calculation of diluted net income per common share as their inclusion would be anti-dilutive (three and six months ended June 30, 2016 – 1,934,452 and 1,841,096, respectively).

The following is a reconciliation of the numerators and denominators of basic and diluted net loss per common share:

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Numerator:
Net loss used to compute net loss per common share:
Basic	$	(7,380	)	$	(6,016	)	$	(14,897	)	$	(9,279	)
Adjustment for change in fair value of liability classified stock options		(30	)		(58	)		(162	)		(100	)
Diluted	$	(7,410	)	$	(6,074	)	$	(15,059	)	$	(9,379	)
Denominator:
Weighted average number of common shares:
Basic		17,997,194			14,408,108			17,971,702			14,401,054
Adjustment for dilutive effect of stock options		18,554			26,494			23,407			27,106
Diluted		18,015,748			14,434,602			17,995,109			14,428,160
Net loss per common share - basic	$	(0.41	)	$	(0.42	)	$	(0.83	)	$	(0.64	)
Net loss per common share - diluted	$	(0.41	)	$	(0.42	)	$	(0.84	)	$	(0.65	)

Fair Value of Financial Instruments

6 Months Ended

Jun. 30, 2017

Fair Value Disclosures [Abstract]

Fair value of financial instruments

5.	Fair value of financial instruments:

We measure certain financial instruments and other items at fair value.

To determine the fair value, we use the fair value hierarchy for inputs used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).

•

Level 1 - Unadjusted quoted prices in active markets for identical instruments.

•

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

•

Level 3 - Inputs are unobservable and reflect the Company’s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.

Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.

The Company’s Level 1 assets include cash and cash equivalents and marketable securities with quoted prices in active markets. The carrying amount of accounts receivables, accounts payable and accrued expenses approximates fair value due to the nature and short-term of those instruments. As quoted prices for the liability classified stock options, included in the consolidated balance sheet as accounts payable and accrued expenses, are not readily available, the Company has used a Black-Scholes pricing model to estimate fair value using Level 3 inputs as defined above.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Accounts Payable and Accrued Expenses

6 Months Ended

Jun. 30, 2017

Payables And Accruals [Abstract]

Accounts Payable and Accrued Expenses

6.	Accounts payable and accrued expenses:

Accounts payable and accrued expenses consisted of the following:

	June 30,		December 31,
	2017		2016
Trade payables	$	1,314	$	1,463
Employee compensation, benefits, and related accruals		975		872
Consulting and contracted research		1,061		1,029
Professional fees		358		93
Other		66		129
Total	$	3,774	$	3,586

Share Capital

6 Months Ended

Jun. 30, 2017

Stockholders Equity Note [Abstract]

Share Capital

7.	Share Capital

(a)

Financing:

On September 13, 2016, the Company completed an underwritten public offering of 3,450,000 of its common shares at a public offering price of $7.50 per common share. The Company received approximately $24.3 million of proceeds, net of underwriting discounts and commissions but before offering expenses.

(b)

Stock-based compensation:

The following table presents stock option activity for the period:

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Outstanding, beginning of period		2,258,237			1,934,734			1,910,823			1,721,472
Granted		29,750			65,450			446,500			299,400
Exercised⁽¹⁾		(3,085	)		(14,283	)		(71,006	)		(30,529	)
Forfeited and expired		(8,005	)		(2,227	)		(9,420	)		(6,669	)
Outstanding, end of period		2,276,897			1,983,674			2,276,897			1,983,674
Exercisable, end of period		1,374,535			1,195,883			1,374,535			1,195,883

⁽¹⁾

During the six months ended June 30, 2017, 63,425 stock options were exercised for the same number of common shares for cash (six months ended June 30, 2016 – 29,270). In the same period, the Company issued 4,405 common shares (six months ended June 30, 2016 – 741) for the cashless exercise of 7,581 stock options (six months ended June 30, 2016 – 1,259).

The fair value of each option granted to employees and non-employees is estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Average risk-free interest rate		2.05	%		1.44	%		2.41	%		1.60	%
Expected volatility		81	%		74	%		81	%		75	%
Average expected term (in years)		7.68			6.14			7.49			6.23
Expected dividend yield		0.00	%		0.00	%		0.00	%		0.00	%

The weighted-average fair value of options granted during the six months ended June 30, 2017 was $6.11 (six months ended June 30, 2016 – $4.90) per option.

Collaboration Agreements

6 Months Ended

Jun. 30, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaboration agreements

8.	Collaboration agreements:

The Company has entered into a number of collaboration agreements with multiple deliverables under which it may have received non-refundable upfront payments. The Company generally recognizes revenue from non-refundable upfront payments ratably over the term of its estimated period of performance of research under its collaboration agreements in the event that such arrangements represent a single unit of accounting.

The collaborations may also include contractual milestone payments, which relate to the achievement of pre-specified research, development, regulatory and commercialization events. The milestone events coincide with the progression of product candidates from research and development, to regulatory approval and through to commercialization. The process of successfully discovering a new product candidate, having it selected by the collaborator for development and having it approved and ultimately sold for a profit is highly uncertain. As such, the milestone payments that the Company may earn from its collaborators involve a significant degree of risk to achieve.

The following table is a summary of the revenue recognized from the Company’s collaborations for the three and six months ended June 30, 2017 and 2016:

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Teva:
Research funding	$	15	$	29	$	30	$	58
Genentech:
Recognition of upfront payment		—		—		—		157
Research funding		—		383		—		766
Total collaboration revenue	$	15	$	412	$	30	$	981

Commitments and Contingencies

6 Months Ended

Jun. 30, 2017

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

9.	Commitments and contingencies:

(a)

Priority access agreement with Medpace Inc. (“Medpace”):

In August 2015, the Company entered into a priority access agreement with Medpace for the provision of certain clinical development services. Under the terms of the agreement, the Company has committed to using Medpace non-exclusively for clinical development services over the five year term of the agreement. In consideration for priority access to Medpace resources and preferred service rates, the Company has committed to $7,000 of services over the term of the agreement, $3,000 of which was paid in the year ended December 31, 2015. Of the amounts paid by the Company in 2015 in connection with the priority access agreement, an aggregate of $2,715 has been recorded as expenses to date for services rendered, and no amount has been classified as current prepaid expenses (December 31, 2016 – $392) and $285 has been classified as long-term prepaid expenses (December 31, 2016 – $408) for the provision of future services as at June 30, 2017.

(b)

License, manufacture and supply agreement:

In March 2017, the Company entered into a license, manufacture and supply agreement with a pharmaceutical contract manufacturing organization for the access and use of certain regulatory documents as well as for the manufacture and supply of clinical and commercial drug product. Under the terms of the agreement, the Company paid an upfront fee of $500 CAD and will be required to pay a low single-digit percentage royalty on net sales of any products developed and commercialized under the agreement.

(c)

Asset purchase agreement with 1st Order Pharmaceuticals, Inc. (“1st Order”):

In April 2017, the Company acquired XEN1101 (previously known as 1OP2198) from 1st Order pursuant to an asset purchase agreement. 1st Order previously acquired 1OP2198 from an affiliate of Valeant Pharmaceuticals International, Inc. (“Valeant”), and the Company has assumed certain financial responsibilities under that agreement. Under the terms of the agreement, the Company paid an upfront fee of $350 and expects to pay an additional $700 in milestones in 2017. Future potential payments to both 1st Order and Valeant include $1,000 in clinical development milestones, up to $13,000 in regulatory milestones, and up to approximately $33,600 in sales-based and other milestones, which includes a $1,500 milestone that may be payable pre-commercially, plus a mid-to-high single-digit percentage royalty on commercial sales.

(d)

Guarantees and indemnifications:

The Company has entered into license and research agreements with third parties that include indemnification provisions that are customary in the industry. These indemnification provisions generally require the Company to compensate the other party for certain damages and costs incurred as a result of third party claims or damages arising from these transactions.

The maximum amount of potential future indemnification is unlimited; however, the Company currently holds commercial and product liability insurance. This insurance limits the Company’s exposure and may enable it to recover a portion of any future amounts paid. Historically, the Company has not made any indemnification payments under such agreements and the Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.

Related Parties

6 Months Ended

Jun. 30, 2017

Related Parties

10.	Related Parties:

Dr. August J. Troendle, an officer and director of Medpace, which provided clinical development services to the Company, was a beneficial owner of more than 5% of the Company’s common shares during 2016. The Company incurred $332 and $764 of clinical development service fees under its priority access agreement and a master services agreement with Medpace for the three and six months ended June 30, 2017, respectively (three and six months ended June 30, 2016 – $568 and $941, respectively.)

Subsequent Event

6 Months Ended

Jun. 30, 2017

Subsequent Events [Abstract]

Subsequent Event

11.	Subsequent Event:

In July 2017, the Company entered into a license agreement with a pharmaceutical company for the access and use of certain regulatory documents to support the development of a potential product candidate. Under the terms of the agreement, the Company is required to pay an upfront fee of $1,000. Future potential payments include $2,000 in clinical development milestones, up to $7,000 in regulatory milestones, which includes $1,000 expected to be paid in 2017, plus a low-to-mid single-digit percentage royalty on net sales of any products developed and commercialized under the agreement.

Net Income (Loss) Per Common Share (Tables)

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Reconciliation of the Numerators and Denominators of Basic and Diluted Net Loss Per Common Share

The following is a reconciliation of the numerators and denominators of basic and diluted net loss per common share:

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Numerator:
Net loss used to compute net loss per common share:
Basic	$	(7,380	)	$	(6,016	)	$	(14,897	)	$	(9,279	)
Adjustment for change in fair value of liability classified stock options		(30	)		(58	)		(162	)		(100	)
Diluted	$	(7,410	)	$	(6,074	)	$	(15,059	)	$	(9,379	)
Denominator:
Weighted average number of common shares:
Basic		17,997,194			14,408,108			17,971,702			14,401,054
Adjustment for dilutive effect of stock options		18,554			26,494			23,407			27,106
Diluted		18,015,748			14,434,602			17,995,109			14,428,160
Net loss per common share - basic	$	(0.41	)	$	(0.42	)	$	(0.83	)	$	(0.64	)
Net loss per common share - diluted	$	(0.41	)	$	(0.42	)	$	(0.84	)	$	(0.65	)

Accounts Payable and Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2017

Payables And Accruals [Abstract]

Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:

	June 30,		December 31,
	2017		2016
Trade payables	$	1,314	$	1,463
Employee compensation, benefits, and related accruals		975		872
Consulting and contracted research		1,061		1,029
Professional fees		358		93
Other		66		129
Total	$	3,774	$	3,586

Share Capital (Tables)

6 Months Ended

Jun. 30, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Option Activity

The following table presents stock option activity for the period:

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Outstanding, beginning of period		2,258,237			1,934,734			1,910,823			1,721,472
Granted		29,750			65,450			446,500			299,400
Exercised⁽¹⁾		(3,085	)		(14,283	)		(71,006	)		(30,529	)
Forfeited and expired		(8,005	)		(2,227	)		(9,420	)		(6,669	)
Outstanding, end of period		2,276,897			1,983,674			2,276,897			1,983,674
Exercisable, end of period		1,374,535			1,195,883			1,374,535			1,195,883

⁽¹⁾

Fair Value Assumptions for Stock Options

The fair value of each option granted to employees and non-employees is estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Average risk-free interest rate		2.05	%		1.44	%		2.41	%		1.60	%
Expected volatility		81	%		74	%		81	%		75	%
Average expected term (in years)		7.68			6.14			7.49			6.23
Expected dividend yield		0.00	%		0.00	%		0.00	%		0.00	%

Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Revenues from Collaborations

The following table is a summary of the revenue recognized from the Company’s collaborations for the three and six months ended June 30, 2017 and 2016:

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Teva:
Research funding	$	15	$	29	$	30	$	58
Genentech:
Recognition of upfront payment		—		—		—		157
Research funding		—		383		—		766
Total collaboration revenue	$	15	$	412	$	30	$	981

Basis of presentation (Details)	6 Months Ended
Basis of presentation (Details)	Jun. 30, 2017
Xenon Pharmaceuticals USA Inc. [Member]
Basis of Presentation [Line Items]
Date of incorporation	Dec. 02, 2016

Net Income (Loss) Per Common Share (Details) - shares	3 Months Ended		6 Months Ended
Net Income (Loss) Per Common Share (Details) - shares	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Anti-dilutive shares excluded from the calculation of income per common share	2,228,637	1,934,452	2,086,072	1,841,096

Net Income (Loss) Per Common Share - Reconciliation of the Numerators and Denominators of Basic and Diluted Net Loss Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net loss used to compute net loss per common share:
Basic	$ (7,380)	$ (6,016)	$ (14,897)	$ (9,279)
Adjustment for change in fair value of liability classified stock options	(30)	(58)	(162)	(100)
Diluted	$ (7,410)	$ (6,074)	$ (15,059)	$ (9,379)
Weighted average number of common shares:
Basic	17,997,194	14,408,108	17,971,702	14,401,054
Adjustment for dilutive effect of stock options	18,554	26,494	23,407	27,106
Diluted	18,015,748	14,434,602	17,995,109	14,428,160
Net loss per common share - basic	$ (0.41)	$ (0.42)	$ (0.83)	$ (0.64)
Net loss per common share - diluted	$ (0.41)	$ (0.42)	$ (0.84)	$ (0.65)

Accounts Payable and Accrued Expenses - Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Trade payables	$ 1,314	$ 1,463
Employee compensation, benefits, and related accruals	975	872
Consulting and contracted research	1,061	1,029
Professional fees	358	93
Other	66	129
Total	$ 3,774	$ 3,586

Share Capital (Details) - USD ($) $ / shares in Units, $ in Millions		6 Months Ended
	Sep. 13, 2016	Jun. 30, 2017	Jun. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average fair value of options granted		$ 6.11	$ 4.90
Underwritten Public Offering [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common shares, net of issuance costs (in Shares)	3,450,000
Common share price (in Dollars per share)	$ 7.50
Proceeds from net of underwriting discounts and commissions Before offering expenses	$ 24.3

Share Capital - Stock Option Activity (Details) - shares

3 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2017

Jun. 30, 2016

Jun. 30, 2017

Jun. 30, 2016

Dec. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Outstanding, beginning of period

2,258,237

1,934,734

1,910,823

1,721,472

Granted

29,750

65,450

446,500

299,400

Exercised

^[1]

(3,085)

(14,283)

(71,006)

(30,529)

Forfeited and expired

(8,005)

(2,227)

(9,420)

(6,669)

Outstanding, end of period

2,276,897

1,983,674

2,276,897

1,983,674

1,910,823

Exercisable, end of period

1,374,535

1,195,883

1,374,535

1,195,883

[1]

Share Capital - Stock Option Activity (Parenthetical) (Details) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Options exercised for Number of Common Shares for cash	63,425	29,270
Common stock issued for cashless exercise	4,405	741
Cashless exercise of stock options	7,581	1,259

Share Capital - Fair Value Assumptions for Stock Options (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Fair Value Assumptions For Stock Options [Abstract]
Average risk-free interest rate	2.05%	1.44%	2.41%	1.60%
Expected volatility	81.00%	74.00%	81.00%	75.00%
Average expected term (in years)	7 years 8 months 5 days	6 years 1 month 20 days	7 years 5 months 27 days	6 years 2 months 23 days
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Collaboration Agreements - Revenue Recognized from Collaborations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue	$ 15	$ 412	$ 30	$ 981
Teva [Member] \| Research Funding [Member] \| Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue	$ 15	29	$ 30	58
Genentech [Member] \| Research Funding [Member] \| Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		$ 383		766
Genentech [Member] \| Recognition of Upfront Payment [Member] \| Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue				$ 157

Commitments and Contingencies (Details) $ in Thousands	1 Months Ended		6 Months Ended	12 Months Ended
Commitments and Contingencies (Details) $ in Thousands	Apr. 30, 2017 USD ($)	Mar. 31, 2017 CAD ($)	Jun. 30, 2017 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Aug. 31, 2015 USD ($)
Commitments and Contingencies [Line Items]
Prepaid expenses, long term			$ 285			$ 408
Asset Purchase Agreement [Member] \| 1st Order Pharmaceuticals, Inc. [Member]
Commitments and Contingencies [Line Items]
Upfront fee paid	$ 350
Asset Purchase Agreement [Member] \| 1st Order Pharmaceuticals, Inc. [Member] \| Scenario, Forecast [Member]
Commitments and Contingencies [Line Items]
Expects to pay an additional milestone payment					$ 700
Asset Purchase Agreement [Member] \| 1st Order Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. [Member] \| Clinical Development Milestones [Member]
Commitments and Contingencies [Line Items]
Future potential payments	1,000
Asset Purchase Agreement [Member] \| 1st Order Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. [Member] \| Regulatory Milestone [Member]
Commitments and Contingencies [Line Items]
Future potential payments	13,000
Asset Purchase Agreement [Member] \| 1st Order Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. [Member] \| Sales-based and Other Milestones [Member]
Commitments and Contingencies [Line Items]
Future potential payments	33,600
Asset Purchase Agreement [Member] \| 1st Order Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. [Member] \| Pre-commercial and Single Digit Percentage Royalty on Commercial Sales Milestone [Member]
Commitments and Contingencies [Line Items]
Future potential payments	$ 1,500
Medpace Clinical Development Service Agreement [Member]
Commitments and Contingencies [Line Items]
Service agreement, term			5 years
Committed service obligation							$ 7,000
Contractual obligation paid				$ 3,000
Expenses for services rendered			$ 2,715
Current prepaid expenses			0			392
Prepaid expenses, long term			$ 285			$ 408
License, Manufacture and Supply Agreement [Member]
Commitments and Contingencies [Line Items]
Upfront fee paid		$ 500

Related Parties (Details) - Medpace Clinical Development Service Agreement [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Related Party Transaction [Line Items]
Clinical development service fees to related parties	$ 332	$ 568	$ 764	$ 941
Dr. August J. Troendle, Officer and Director [Member] \| Minimum [Member]
Related Party Transaction [Line Items]
Percentage of ownership					5.00%

Subsequent Event (Details) - Subsequent Event [Member] - License Agreement [Member] $ in Thousands	1 Months Ended
	Jul. 31, 2017 USD ($)
Subsequent Event [Line Items]
Upfront fee payable	$ 1,000
Clinical Development Milestones [Member]
Subsequent Event [Line Items]
Future potential payments	2,000
Regulatory Milestone [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Future potential payments	7,000
Single-Digit Percentage Royalty on Net Sales [Member]
Subsequent Event [Line Items]
Future potential payments	$ 1,000